Paul Tudor Jones's HALO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 61,683 shares of Halozyme Therapeutics, Inc. (HALO) worth $4.52 M, representing 0.01% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2020, adding 71,827 shares. Largest reduction occurred in Q4 2020, reducing 68,415 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2015 | +26,655 | New Buy | 26,655 | $13.43 |
| Q4 2015 | -26,655 | Sold Out | 26,655 | $0.00 |
| Q2 2017 | +46,103 | New Buy | 46,103 | $12.82 |
| Q3 2017 | -27,338 | Reduce 59.30% | 18,765 | $17.37 |
| Q4 2017 | +11,872 | Add 63.27% | 30,637 | $20.27 |
| Q1 2018 | -13,264 | Reduce 43.29% | 17,373 | $19.57 |
| Q2 2018 | -17,373 | Sold Out | 17,373 | $0.00 |
| Q3 2020 | +89,200 | New Buy | 89,200 | $26.28 |
| Q4 2020 | -68,415 | Reduce 76.70% | 20,785 | $42.72 |
| Q1 2021 | -20,785 | Sold Out | 20,785 | $0.00 |
| Q2 2025 | +39,140 | New Buy | 39,140 | $52.02 |
| Q3 2025 | +22,543 | Add 57.60% | 61,683 | $73.34 |
Paul Tudor Jones's Halozyme Therapeutics Investment FAQs
Paul Tudor Jones first purchased Halozyme Therapeutics, Inc. (HALO) in Q3 2015, acquiring 26,655 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Halozyme Therapeutics, Inc. (HALO) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2020, adding 89,200 shares worth $2.34 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 61,683 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $4.52 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Halozyme Therapeutics, Inc. (HALO) was 89,200 shares, as reported at the end of Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.